Eli Lilly Surges on Zepbound Sleep Apnea Drug Approval
Eli Lilly's stock climbs as Zepbound becomes the first FDA-approved treatment for sleep apnea, boosting investor confidence and market position.
Eli Lilly saw gains after Zepbound was approved as a sleep apnea treatment.